S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
NASDAQ:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.16
$0.39
52-Week Range
N/A
Volume
1.27 million shs
Average Volume
160,047 shs
Market Capitalization
$10.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Medicenna Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
∞ Upside
$2.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.17) to ($0.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.92 out of 5 stars

Medical Sector

836th out of 950 stocks

Pharmaceutical Preparations Industry

375th out of 426 stocks


MDNA stock logo

About Medicenna Therapeutics Stock (NASDAQ:MDNA)

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.


MDNA Stock News Headlines

Medicenna Therapeutics Corp MDNA
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Medicenna Announces Appointment of New Auditor
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Medicenna Therapeutics Names Humphrey Gardner CMO
The Latest Analyst Ratings for Medicenna Therapeutics
Medicenna Therapeutics's Earnings: A Preview
See More Headlines
Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/02/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MDNA
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$3.00
Low Stock Price Target
$2.50
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-7,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.32 per share

Miscellaneous

Free Float
46,587,000
Market Cap
$10.93 million
Optionable
Not Optionable
Beta
1.30
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Fahar Merchant Ph.D. (Age 66)
    Founder, Chairman, President & CEO
    Comp: $327.41k
  • Ms. Rosemina Merchant B.Sc. (Age 66)
    M.E.Sc, Founder & Chief Development Officer
    Comp: $262.62k
  • Mr. Jeff Caravella M.B.A.
    Chief Financial Officer
  • Mr. Brent Meadows M.B.A.
    Chief Business Officer
  • Dr. Humphrey A. R. Gardner FCAP
    M.D., Chief Medical Officer
  • Dr. Samuel R. Denmeade M.D.
    Scientific Advisor














MDNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings
or view top-rated stocks.

What is Medicenna Therapeutics' stock price target for 2024?

2 brokerages have issued 1-year price objectives for Medicenna Therapeutics' stock. Their MDNA share price targets range from $2.50 to $3.00. On average, they predict the company's share price to reach $2.75 in the next year.
View analysts price targets for MDNA
or view top-rated stocks among Wall Street analysts.

How were Medicenna Therapeutics' earnings last quarter?

Medicenna Therapeutics Corp. (NASDAQ:MDNA) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. During the same quarter in the previous year, the firm earned ($0.06) earnings per share.

This page (NASDAQ:MDNA) was last updated on 3/2/2024 by MarketBeat.com Staff